Immune Design (Immune Design) Ending Cash Position : $78.14 Mil (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Immune Design Ending Cash Position?

Immune Design's Ending Cash Position for the quarter that ended in Dec. 2018 was $78.14 Mil.

Immune Design's quarterly Ending Cash Position declined from Jun. 2018 ($73.63 Mil) to Sep. 2018 ($68.74 Mil) but then increased from Sep. 2018 ($68.74 Mil) to Dec. 2018 ($78.14 Mil).

Immune Design's annual Ending Cash Position increased from Dec. 2016 ($45.21 Mil) to Dec. 2017 ($72.45 Mil) and increased from Dec. 2017 ($72.45 Mil) to Dec. 2018 ($78.14 Mil).

Immune Design Ending Cash Position Historical Data

The historical data trend for Immune Design's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Ending Cash Position Chart

Immune Design Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Ending Cash Position

Get a 7-Day Free Trial

75.35

112.92

45.21

72.45

78.14

Immune Design Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Ending Cash Position	Get a 7-Day Free Trial															72.45	72.37	73.63	68.74	78.14

Immune Design Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Immune Design's Ending Cash Position for the fiscal year that ended in Dec. 2018 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	78.654	+	-0.513
	=	78.14

Immune Design's Ending Cash Position for the quarter that ended in Dec. 2018 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	68.735	+	9.406
	=	78.14

Immune Design Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Immune Design's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Immune Design (Immune Design) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102

Website

http://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Executives

William R Ringo	director
David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya	director, officer: President and CEO	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005